• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

RECIST persists despite flaws

Article

Long-held notions about the use of anatomic measurement to gauge response to cancer therapy don't hold up in a world redefined by molecularly based medicine.

Long-held notions about the use of anatomic measurement to gauge response to cancer therapy don't hold up in a world redefined by molecularly based medicine.

Dr. Wolfgang Weber brought that message to the 2005 Academy of Molecular Imaging meeting in March. Weber, an assistant professor of radiology at the University of California, Los Angeles, argued that the two most widely used standards for measuring therapeutic response no longer make the grade.

Weber's criticism was directed at criteria developed by the World Health Organization and the Response Evaluation Criteria in Solid Tumors (RECIST). Both use CT to measure anatomic changes in tumor size in order to calculate their response to chemo- and radiotherapy. The WHO criteria, developed in the 1970s, describe a positive response as a 50% reduction of two perpendicular tumor diameters drawn across the lesion (D1 x D2). RECIST, published in 1990, uses changes in the maximum tumor diameter for assessments. A positive response with RECIST equates to a 30% decrease in the maximum diameter.

Both systems are based on outdated notions about measurement accuracy and the limitations of resolution possible with circa-1975 CT scanners, according to Weber. The framers of the WHO and RECIST criteria could not have anticipated the performance of cytostatic drugs that kill cancers without affecting tumor size, he said.

These problems have led to assessment errors. RECIST criteria, for instance, concluded that the lung cancer drug erlotinib produced only an 8.9% positive response, while the clinical trial of 730 patients credited the drug for a nearly 50% increase in the median survival.

Weber admitted that oncologists still have good technical reasons to use the WHO and RECIST guidelines, but he asked the audience to consider how molecular imaging, especially quantitative measures such as standard uptake values, could do better.

Related Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.